vs
Alkermes plc.（ALKS）与Healthpeak Properties（DOC）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是Alkermes plc.的1.9倍（$719.4M vs $384.5M），Healthpeak Properties净利率更高（73.2% vs 12.8%，领先60.3%），Healthpeak Properties同比增速更快（3.1% vs -10.6%），Healthpeak Properties自由现金流更多（$357.0M vs $170.0M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 4.8%）
Alkermes plc是一家全产业链布局的生物制药企业，专注于精神障碍与神经系统疾病相关药物的研发。公司1987年由迈克尔·沃尔创立，2011年9月与原Élan集团旗下的药物制剂及生产部门Elan Drug Technologies合并，总部位于都柏林，在马萨诸塞州沃尔瑟姆设有研发中心，俄亥俄州威尔明顿建有生产基地。
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
ALKS vs DOC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $384.5M | $719.4M |
| 净利润 | $49.3M | $114.0M |
| 毛利率 | 88.0% | — |
| 营业利润率 | 15.1% | 17.4% |
| 净利率 | 12.8% | 73.2% |
| 营收同比 | -10.6% | 3.1% |
| 净利润同比 | -66.3% | 2406.4% |
| 每股收益（稀释后） | $0.29 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $384.5M | $719.4M | ||
| Q3 25 | $394.2M | $705.9M | ||
| Q2 25 | $390.7M | $694.3M | ||
| Q1 25 | $306.5M | $702.9M | ||
| Q4 24 | $430.0M | $698.0M | ||
| Q3 24 | $378.1M | $700.4M | ||
| Q2 24 | $399.1M | $695.5M | ||
| Q1 24 | $350.4M | $606.6M |
| Q4 25 | $49.3M | $114.0M | ||
| Q3 25 | $82.8M | $-117.1M | ||
| Q2 25 | $87.1M | $31.7M | ||
| Q1 25 | $22.5M | $42.8M | ||
| Q4 24 | $146.5M | $4.5M | ||
| Q3 24 | $92.4M | $85.9M | ||
| Q2 24 | $91.4M | $146.0M | ||
| Q1 24 | $36.8M | $6.7M |
| Q4 25 | 88.0% | — | ||
| Q3 25 | 86.9% | 58.6% | ||
| Q2 25 | 87.3% | 60.2% | ||
| Q1 25 | 83.9% | 61.1% | ||
| Q4 24 | 85.6% | 60.3% | ||
| Q3 24 | 83.3% | 60.0% | ||
| Q2 24 | 84.6% | 60.6% | ||
| Q1 24 | 83.3% | 59.8% |
| Q4 25 | 15.1% | 17.4% | ||
| Q3 25 | 22.6% | 9.2% | ||
| Q2 25 | 23.8% | 5.7% | ||
| Q1 25 | 4.5% | 7.7% | ||
| Q4 24 | 37.8% | -2.2% | ||
| Q3 24 | 27.7% | 14.1% | ||
| Q2 24 | 27.5% | 22.3% | ||
| Q1 24 | 12.4% | 3.7% |
| Q4 25 | 12.8% | 73.2% | ||
| Q3 25 | 21.0% | -16.6% | ||
| Q2 25 | 22.3% | 4.6% | ||
| Q1 25 | 7.3% | 6.1% | ||
| Q4 24 | 34.1% | 0.7% | ||
| Q3 24 | 24.4% | 12.3% | ||
| Q2 24 | 22.9% | 21.0% | ||
| Q1 24 | 10.5% | 1.1% |
| Q4 25 | $0.29 | $0.16 | ||
| Q3 25 | $0.49 | $-0.17 | ||
| Q2 25 | $0.52 | $0.05 | ||
| Q1 25 | $0.13 | $0.06 | ||
| Q4 24 | $0.88 | $0.02 | ||
| Q3 24 | $0.55 | $0.12 | ||
| Q2 24 | $0.53 | $0.21 | ||
| Q1 24 | $0.21 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $388.6M | $467.5M |
| 总债务越低越好 | — | $9.8B |
| 股东权益账面价值 | $1.8B | $7.5B |
| 总资产 | $2.5B | $20.3B |
| 负债/权益比越低杠杆越低 | — | 1.31× |
8季度趋势，按日历期对齐
| Q4 25 | $388.6M | $467.5M | ||
| Q3 25 | $616.4M | $91.0M | ||
| Q2 25 | $521.2M | $89.4M | ||
| Q1 25 | $399.8M | $70.6M | ||
| Q4 24 | $291.1M | $119.8M | ||
| Q3 24 | $396.3M | $180.4M | ||
| Q2 24 | $535.1M | $106.9M | ||
| Q1 24 | $420.8M | $101.8M |
| Q4 25 | — | $9.8B | ||
| Q3 25 | — | $9.1B | ||
| Q2 25 | — | $9.0B | ||
| Q1 25 | — | $8.9B | ||
| Q4 24 | — | $8.7B | ||
| Q3 24 | — | $8.6B | ||
| Q2 24 | — | $8.6B | ||
| Q1 24 | — | $8.8B |
| Q4 25 | $1.8B | $7.5B | ||
| Q3 25 | $1.7B | $7.6B | ||
| Q2 25 | $1.6B | $7.9B | ||
| Q1 25 | $1.5B | $8.2B | ||
| Q4 24 | $1.5B | $8.4B | ||
| Q3 24 | $1.3B | $8.6B | ||
| Q2 24 | $1.3B | $8.8B | ||
| Q1 24 | $1.3B | $8.9B |
| Q4 25 | $2.5B | $20.3B | ||
| Q3 25 | $2.3B | $19.6B | ||
| Q2 25 | $2.3B | $19.8B | ||
| Q1 25 | $2.1B | $19.8B | ||
| Q4 24 | $2.1B | $19.9B | ||
| Q3 24 | $2.2B | $20.0B | ||
| Q2 24 | $2.2B | $20.2B | ||
| Q1 24 | $2.1B | $20.5B |
| Q4 25 | — | 1.31× | ||
| Q3 25 | — | 1.20× | ||
| Q2 25 | — | 1.14× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | — | 1.04× | ||
| Q3 24 | — | 1.00× | ||
| Q2 24 | — | 0.98× | ||
| Q1 24 | — | 0.99× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $170.1M | $1.3B |
| 自由现金流经营现金流 - 资本支出 | $170.0M | $357.0M |
| 自由现金流率自由现金流/营收 | 44.2% | 49.6% |
| 资本支出强度资本支出/营收 | 0.0% | 124.4% |
| 现金转化率经营现金流/净利润 | 3.45× | 10.99× |
| 过去12个月自由现金流最近4个季度 | $480.3M | — |
8季度趋势，按日历期对齐
| Q4 25 | $170.1M | $1.3B | ||
| Q3 25 | $101.7M | $315.0M | ||
| Q2 25 | $150.2M | $363.5M | ||
| Q1 25 | $98.8M | $279.4M | ||
| Q4 24 | $190.4M | $1.1B | ||
| Q3 24 | $81.6M | $318.2M | ||
| Q2 24 | $146.0M | $316.2M | ||
| Q1 24 | $21.1M | $152.6M |
| Q4 25 | $170.0M | $357.0M | ||
| Q3 25 | $84.4M | — | ||
| Q2 25 | $137.2M | — | ||
| Q1 25 | $88.7M | — | ||
| Q4 24 | $180.6M | $333.7M | ||
| Q3 24 | $73.3M | — | ||
| Q2 24 | $138.9M | — | ||
| Q1 24 | $12.8M | — |
| Q4 25 | 44.2% | 49.6% | ||
| Q3 25 | 21.4% | — | ||
| Q2 25 | 35.1% | — | ||
| Q1 25 | 28.9% | — | ||
| Q4 24 | 42.0% | 47.8% | ||
| Q3 24 | 19.4% | — | ||
| Q2 24 | 34.8% | — | ||
| Q1 24 | 3.6% | — |
| Q4 25 | 0.0% | 124.4% | ||
| Q3 25 | 4.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 2.3% | 105.6% | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 3.45× | 10.99× | ||
| Q3 25 | 1.23× | — | ||
| Q2 25 | 1.72× | 11.48× | ||
| Q1 25 | 4.40× | 6.52× | ||
| Q4 24 | 1.30× | 235.43× | ||
| Q3 24 | 0.88× | 3.71× | ||
| Q2 24 | 1.60× | 2.17× | ||
| Q1 24 | 0.57× | 22.85× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALKS
| Vivitrol | $124.1M | 32% |
| Aristada And Aristada Initio | $97.2M | 25% |
| LYBALVI | $94.1M | 24% |
| Royalty | $65.7M | 17% |
| Manufacturing Revenue | $3.3M | 1% |
DOC
暂无分部数据
